Skip to content

NYSE · CIK 0000784199

AORT ARTIVION, INC.

Insider trading from SEC Form 4. Last filing Mar 12, 2025. Close $21.26 on Oct 9, 2026, +6% from the 52-week low and -55% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company

Price and insider trades, last year

AORT, daily close, last year. insider buy insider sellDot size follows the dollar value (largest $2.2M).

Signals

Open-market buys and sells at ARTIVION, INC., scored.

ScoreSideInsiderValueSharesHoldings changePrice contextFiled
10Weaksell 610b5-1Davis John E
Chief Commercial Officer
$357k15,100-7%0% from low · -26% from high
12Weaksell 610b5-1Holloway Jean F
SVP, General Counsel
$426k18,020-8%0% from low · -26% from high
37Weaksell 6Holloway Jean F
SVP, General Counsel
$53k2,124-1%+2% from low · -22% from high
36Weaksell 6Stanton Marshall S.
SVP, Clinical & MD Affair
$40k1,603-1%+2% from low · -22% from high
38Weaksell 6Davis John E
Chief Commercial Officer
$65k2,618-1%+2% from low · -22% from high
47Moderatesell 6Berry Lance A
Executive VP, CFO
$122k4,909-3%+2% from low · -22% from high
35Weaksell 6Horton Amy
VP, Chief Accounting Officer
$26k1,048-1%+2% from low · -22% from high
35Weaksell 610b5-1Mackin James P
President & CEO
$2.2M88,439-10%+2% from low · -22% from high
30Weaksell 6Holloway Jean F
SVP, General Counsel
$12k472-0%+4% from low · -20% from high
39WeakbuySEMEDO ANTHONY B.
director
$53k2,100+6%+4% from low · -20% from high
41Moderatesell 6Stanton Marshall S.
SVP, Clinical & MD Affair
$128k4,687-6%+14% from low · -12% from high
46Moderatesell 6Berry Lance A
Executive VP, CFO
$89k3,259-4%+14% from low · -12% from high
42Moderatesell 6Davis John E
Chief Commercial Officer
$176k6,457-4%+14% from low · -12% from high
41Moderatesell 6Holloway Jean F
SVP, General Counsel
$146k5,335-3%+14% from low · -12% from high
65Notablesell 6Mackin James P
President & CEO
$1.2M42,156-6%+14% from low · -12% from high
39Weaksell 6Horton Amy
VP, Chief Accounting Officer
$91k3,323-2%+14% from low · -12% from high
43Moderatesell 3Holloway Jean F
SVP, General Counsel
$243k8,070-5%+23% from low · 0% from high
41Moderatesell 3Horton Amy
VP, Chief Accounting Officer
$129k4,425-3%+22% from low · -0% from high
41Moderatesell 3Horton Amy
VP, Chief Accounting Officer
$128k4,329-3%+22% from low · -0% from high
28Weaksell 310b5-1GREEN ANDREW M
VP Regulatory
$229k7,618-19%+22% from low · -0% from high

Congressional trades

3 trades in AORT disclosed by members of Congress under the STOCK Act. All congressional trades.

MemberTypeAssetAmountTradedFiled
Gilbert Ray Cisneros, Jr.
House · D-CA
PurchaseAORT
Artivion, Inc. Common Stock
$1,001 to $15kAug 20, 2026
21 days after the trade
Gilbert Ray Cisneros, Jr.
House · D-CA
PurchaseAORT
Artivion, Inc. Common Stock
$1,001 to $15kJul 16, 2026
50 days after the trade
Gilbert Ray Cisneros, Jr.
House · D-CA
Partial saleAORT
Artivion, Inc. Common Stock
$1,001 to $15kOct 9, 2025
40 days after the trade

Transactions

The last 57 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Mar 11, 2025Holloway Jean F
SVP, General Counsel
MOption exercise
Common Stock10b5-1
+19,092$21.55$411k215,204Mar 12, 2025
Mar 11, 2025Davis John E
Chief Commercial Officer
MOption exercise
Common Stock10b5-1
+15,910$21.55$343k223,878Mar 12, 2025
Mar 11, 2025Davis John E
Chief Commercial Officer
SOpen-market sale
Common Stock10b5-1
-15,100$23.61$357k208,778Mar 12, 2025
Mar 11, 2025Holloway Jean F
SVP, General Counsel
SOpen-market sale
Common Stock10b5-1
-18,020$23.61$426k197,184Mar 12, 2025
Mar 11, 2025Davis John E
Chief Commercial Officer
MOption exercise
Stock Options (Right to buy)derivative10b5-1
-15,910$0.00$00Mar 12, 2025
Mar 11, 2025Holloway Jean F
SVP, General Counsel
MOption exercise
Stock Options (Right to buy)derivative10b5-1
-19,092$0.00$00Mar 12, 2025
Mar 6, 2025Holloway Jean F
SVP, General Counsel
AGrant or award
Common Stock
+25,493$0.00$0198,236Mar 10, 2025
Mar 6, 2025Stanton Marshall S.
SVP, Clinical & MD Affair
AGrant or award
Common Stock
+19,240$0.00$0117,483Mar 10, 2025
Mar 6, 2025Davis John E
Chief Commercial Officer
AGrant or award
Common Stock
+25,654$0.00$0210,586Mar 10, 2025
Mar 6, 2025Mackin James P
President & CEO
AGrant or award
Common Stock10b5-1
+115,701$0.00$0878,107Mar 10, 2025
Mar 6, 2025Berry Lance A
Executive VP, CFO
AGrant or award
Common Stock
+48,100$0.00$0158,340Mar 10, 2025
Mar 6, 2025Horton Amy
VP, Chief Accounting Officer
AGrant or award
Common Stock
+10,261$0.00$0147,699Mar 10, 2025
Mar 6, 2025Berry Lance A
Executive VP, CFO
SOpen-market sale
Common Stock
-4,909$24.80$122k153,431Mar 10, 2025
Mar 6, 2025Mackin James P
President & CEO
SOpen-market sale
Common Stock10b5-1
-17,739$24.80$440k860,368Mar 10, 2025
Mar 6, 2025Horton Amy
VP, Chief Accounting Officer
SOpen-market sale
Common Stock
-1,048$24.80$26k146,651Mar 10, 2025
Mar 6, 2025Davis John E
Chief Commercial Officer
SOpen-market sale
Common Stock
-2,618$24.80$65k207,968Mar 10, 2025
Mar 6, 2025Stanton Marshall S.
SVP, Clinical & MD Affair
SOpen-market sale
Common Stock
-1,603$24.80$40k115,880Mar 10, 2025
Mar 6, 2025Holloway Jean F
SVP, General Counsel
SOpen-market sale
Common Stock
-2,124$24.80$53k196,112Mar 10, 2025
Mar 6, 2025Mackin James P
President & CEO
MOption exercise
Common Stock10b5-1
+75,615$21.55$1.6M935,983Mar 10, 2025
Mar 6, 2025Mackin James P
President & CEO
SOpen-market sale
Common Stock10b5-1
-70,700$24.76$1.8M865,283Mar 10, 2025
Mar 6, 2025Mackin James P
President & CEO
MOption exercise
Stock Options (Right to buy)derivative10b5-1
-75,615$0.00$00Mar 10, 2025
Mar 5, 2025Holloway Jean F
SVP, General Counsel
SOpen-market sale
Common Stock
-472$25.29$12k172,743Mar 6, 2025
Mar 5, 2025SEMEDO ANTHONY B.
director
POpen-market purchase
Common Stock
+1,500$25.33$38k35,659Mar 5, 2025
Mar 5, 2025SEMEDO ANTHONY B.
director
POpen-market purchase
Common Stockindirect: By Spouse
+600$25.25$15k600Mar 5, 2025
Feb 28, 2025Mackin James P
President & CEO
AGrant or award
Common Stock
+98,524$0.00$0762,406Mar 4, 2025
Feb 28, 2025Stanton Marshall S.
SVP, Clinical & MD Affair
AGrant or award
Common Stock
+18,398$0.00$098,243Mar 4, 2025
Feb 28, 2025Horton Amy
VP, Chief Accounting Officer
AGrant or award
Common Stock
+6,297$0.00$0137,438Mar 4, 2025
Feb 28, 2025Davis John E
Chief Commercial Officer
AGrant or award
Common Stock
+24,301$0.00$0184,932Mar 4, 2025
Feb 28, 2025Berry Lance A
Executive VP, CFO
AGrant or award
Common Stock
+34,435$0.00$0110,240Mar 4, 2025
Feb 28, 2025Holloway Jean F
SVP, General Counsel
AGrant or award
Common Stock
+23,416$0.00$0173,215Mar 4, 2025
Feb 24, 2025Horton Amy
VP, Chief Accounting Officer
SOpen-market sale
Common Stock
-1,706$27.31$47k132,758Feb 26, 2025
Feb 24, 2025Mackin James P
President & CEO
SOpen-market sale
Common Stock
-16,664$27.31$455k689,374Feb 26, 2025
Feb 24, 2025Holloway Jean F
SVP, General Counsel
SOpen-market sale
Common Stock
-2,385$27.31$65k152,749Feb 26, 2025
Feb 24, 2025Davis John E
Chief Commercial Officer
SOpen-market sale
Common Stock
-2,846$27.31$78k164,242Feb 26, 2025
Feb 24, 2025Berry Lance A
Executive VP, CFO
SOpen-market sale
Common Stock
-3,259$27.31$89k75,805Feb 26, 2025
Feb 24, 2025Stanton Marshall S.
SVP, Clinical & MD Affair
SOpen-market sale
Common Stock
-2,299$27.31$63k82,233Feb 26, 2025
Feb 24, 2025Davis John E
Chief Commercial Officer
SOpen-market sale
Common Stock
-591$27.31$16k163,651Feb 26, 2025
Feb 24, 2025Holloway Jean F
SVP, General Counsel
SOpen-market sale
Common Stock
-490$27.31$13k152,259Feb 26, 2025
Feb 24, 2025Stanton Marshall S.
SVP, Clinical & MD Affair
SOpen-market sale
Common Stock
-470$27.31$13k81,763Feb 26, 2025
Feb 24, 2025Mackin James P
President & CEO
SOpen-market sale
Common Stock
-13,784$27.31$376k675,590Feb 26, 2025
Feb 24, 2025Horton Amy
VP, Chief Accounting Officer
SOpen-market sale
Common Stock
-814$27.31$22k131,944Feb 26, 2025
Feb 24, 2025Davis John E
Chief Commercial Officer
SOpen-market sale
Common Stock
-985$27.31$27k162,666Feb 26, 2025
Feb 24, 2025Horton Amy
VP, Chief Accounting Officer
SOpen-market sale
Common Stock
-318$27.31$8,683131,626Feb 26, 2025
Feb 24, 2025Stanton Marshall S.
SVP, Clinical & MD Affair
SOpen-market sale
Common Stock
-672$27.31$18k81,091Feb 26, 2025
Feb 24, 2025Holloway Jean F
SVP, General Counsel
SOpen-market sale
Common Stock
-810$27.31$22k151,449Feb 26, 2025
Feb 24, 2025Mackin James P
President & CEO
SOpen-market sale
Common Stock
-6,812$27.31$186k668,778Feb 26, 2025
Feb 24, 2025Horton Amy
VP, Chief Accounting Officer
SOpen-market sale
Common Stock
-485$27.31$13k131,141Feb 26, 2025
Feb 24, 2025Holloway Jean F
SVP, General Counsel
SOpen-market sale
Common Stock
-1,650$27.31$45k149,799Feb 26, 2025
Feb 24, 2025Mackin James P
President & CEO
SOpen-market sale
Common Stock
-4,896$27.31$134k663,882Feb 26, 2025
Feb 24, 2025Davis John E
Chief Commercial Officer
SOpen-market sale
Common Stock
-2,035$27.31$56k160,631Feb 26, 2025
Feb 24, 2025Stanton Marshall S.
SVP, Clinical & MD Affair
SOpen-market sale
Common Stock
-1,246$27.31$34k79,845Feb 26, 2025
Dec 12, 2024Horton Amy
VP, Chief Accounting Officer
GGift
Common Stock
-1,100$0.00$0134,464Dec 13, 2024
Dec 11, 2024Holloway Jean F
SVP, General Counsel
SOpen-market sale
Common Stock
-4,035$30.25$122k157,897Dec 12, 2024
Dec 11, 2024Holloway Jean F
SVP, General Counsel
SOpen-market sale
Common Stock
-4,035$30.00$121k153,862Dec 12, 2024
Dec 6, 2024Horton Amy
VP, Chief Accounting Officer
SOpen-market sale
Common Stock
-4,425$29.05$129k135,564Dec 10, 2024
Dec 6, 2024Horton Amy
VP, Chief Accounting Officer
SOpen-market sale
Common Stock
-4,329$29.66$128k135,660Dec 9, 2024
Dec 4, 2024GREEN ANDREW M
VP Regulatory
SOpen-market sale
Common Stock10b5-1
-7,618$30.00$229k33,503Dec 4, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

AORT insider trading: ARTIVION, INC. | InsiderTell